UPDATE: Citi Downgrades Biogen (BIIB) to Neutral

March 21, 2019 4:01 PM
(Updated - March 22, 2019 5:43 AM EDT)

(updated to add analyst comment)

Citi analyst Robyn Karnauskas downgraded Biogen (NASDAQ: BIIB) from Buy to Neutral with a price target of $230.00 (from $470.00)

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $320.59 yesterday.

Categories

Analyst Comments Analyst PT Change Downgrades Hot Downgrades

Next Articles